S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in

(DNDNQ) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.


Lantern Pharma Starts U.S. IPO Process
April 19, 2020 |  seekingalpha.com
Dendreon Corp (DNDNQ) - Options Chain
March 26, 2020 |  www.fool.com
Wednesday's Health Winners & Losers
March 18, 2019 |  www.thestreet.com
See More Headlines

Industry, Sector and Symbol

Industry N/A
Previous SymbolNASDAQ:DNDN
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive DNDNQ News and Ratings via Email

Sign-up to receive the latest news and ratings for DNDNQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

(DNDNQ) (OTCMKTS:DNDNQ) Frequently Asked Questions

What stocks does MarketBeat like better than (DNDNQ)?

Wall Street analysts have given (DNDNQ) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (DNDNQ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were (DNDNQ)'s earnings last quarter?

(DNDNQ) (OTCMKTS:DNDNQ) released its earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biotechnology company earned $73.10 million during the quarter, compared to the consensus estimate of $78.72 million. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.44) earnings per share.
View (DNDNQ)'s earnings history

What is (DNDNQ)'s stock symbol?

(DNDNQ) trades on the OTCMKTS under the ticker symbol "DNDNQ."

How do I buy shares of (DNDNQ)?

Shares of DNDNQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is (DNDNQ)'s official website?

The official website for (DNDNQ) is www.dendreon.com.

Where are (DNDNQ)'s headquarters?

(DNDNQ) is headquartered at 601 Union St Ste 4900, SEATTLE, WA 98101-3906, United States.

How can I contact (DNDNQ)?

(DNDNQ)'s mailing address is 601 Union St Ste 4900, SEATTLE, WA 98101-3906, United States. The biotechnology company can be reached via phone at +1-206-2197815.

This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.